LoginSignup
Imagen de perfil
Adam
@InvestAdam
9Lun·

$OCGN (+0,97 %) Is there an entry opportunity now and is the correction coming? The forecast looks good. What do you think?

1
3 Comentarios
Imagen de perfil
Ella Marie Waschbär@DividendenWaschbaer
9Lun
The best time to start is always now

If you are convinced by the share.
•
2
•
Imagen de perfil
Enrique@Dividenden_Monteur
9Lun
And what is the investment case for the company?
••
Imagen de perfil
Adam@InvestAdam
9Lun
@Der_Dividenden_Monteur A gene therapy for the treatment of achromatopsia. Ocugen-001 is currently in Phase 3 trials and has the potential to be the first approved gene therapy for this rare disease. In addition, Ocugen-010 looks promising for the treatment of Usher syndrome. Ocugen also has strong partnerships with leading companies in ophthalmology, including Biogen and Astellas Pharma.
•
2
•
Únase a la conversación
InscríbaseInicio de sesión